A new model for communicating risk information in direct-to-consumer print advertisements

Drug Information Journal

Volumn 41, Issue 1, 2007, Pages 111-127

  Stotka, Jennifer L ^a   Rotelli, Matthew D ^a   Dowsett, Sherie A ^a   Elsner, Mary W ^a   Holdsworth, Stacy M ^a   Pitts, Peter J ^b   McAvoy, David R ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Center for Medicine in the Public Interest   (United States)

Author keywords

Brief summary; Communication; Direct to consumer (DTC) advertising; Highlight section; Risk information

Indexed keywords

ADULT; ADVERTIZING; ARTICLE; CONSUMER; DRUG INFORMATION; FEMALE; HEALTH HAZARD; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STATISTICAL ANALYSIS;

EID: 33846438986     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150704100112     Document Type: Article

References (10)

1. Aikin KJ, Swasy JL, Braman AC. Patient and physician attitudes and behaviors associated with DTC promotion of prescription drugs-Summary of FDA survey research results. 2004. Food and Drug Administration. Available at: http://www.fda.gov/cder/ddmac/Final%20Report/FRfinal 111904.pdf. Accessed August 23, 2006.
2. Food and Drug Administration. Guidance for industry. Brief summary: Disclosing risk information in consumer-directed print advertisements, 2004. Available at: http://www.fda.gov/cber/ gdlns/consumad.pdf. Accessed August 23, 2006.
3. Robinson AR, Hohmann KB, Rifkin JI, et al. Direct-to-consumer pharmaceutical advertising: physician and public opinion and potential effects on the physician-patient relationship. Arch Intern Med. 2004;164:427-432.
4. Rosenthal MB, Berndt ER, Donohue JM, Frank RG, Epstein AM. Promotion of prescription drugs to consumers. N Engl J Med. 2002;346:498-505.
5. Berndt ER. To inform or persuade? Direct-to-consumer advertising of prescription drugs. N Engl J Med. 2005;352:325-328.
6. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095-3105.
7. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41-55.
8. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc. 1984;79:516-524.
9. Woloshin S, Schwartz LE, Welch HG. The value of benefit data in direct-to-consumer drug ads. Health Affairs. April 28, 2004. Available at http://content.healthaffairs.org/cgi/content/ abstract/hlthaff.w4.234v1. Accessed August 23, 2006.
10. The Henry J. Kaiser Family Foundation. Understanding the effects of direct-to-consumer prescription drug advertising. November 2001. Available at http://www.kff.org/rxdrugs/upload/ Understanding-the-Effects-of-Direct-to- Consumer-Prescription-Drug-Advertising-Report.pdf. Accessed August 23, 2006.